Favorable safety, tolerability and pharmacokinetic results from the trial warrant further investigation, and the company will actively pursue the advancement of INV-202 into later-stage clinical trials.
With encouraging Phase 1 results and supportive preclinical package, Inversago is looking forward to launching Phase 2 clinical development for INV-202.
The CB1 receptor biology and its therapeutic profile are well documented, both clinically and pre-clinically.
In the early 2000s, several major pharmaceutical companies invested massively in this biology, demonstrating the prolific therapeutic benefits a CB1 blockade could provide to patients afflicted with the metabolic syndrome and its complications.
Peripherally-acting CB1 blockers, such as Inversago's first-in-class INV-202, have the potential to provide the same clinical benefits without the previous class-associated psychiatric effects linked to brain target engagement.
Development of a safe and potent peripheral CB1 blockade represents an opportunity to address a significant number of unmet medical needs affecting a growing number of patients globally.
Located in Montreal, Inversago Pharma is a privately-owned Canadian biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting CB1 inverse agonists.
Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Nephropathy, Non-Alcoholic Steatohepatitis, complications from obesity, Hypertriglyceridemia, Type 1 Diabetes and Prader-Willi Syndrome, as well as fibrotic indications like Progressive Fibrosis Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review